medigraphic.com
Colegio de Medicina Interna de México.

2023, Number 4

<< Back Next >>

Med Int Mex 2023; 39 (4)

Correlation of serum calcium with the BISAP scale in acute pancreatitis

Ríos JF, Tavera JML, Villarreal RE

Language: Spanish
References: 24
Page: 610-615
PDF size: 202.64 Kb.


ABSTRACT

Objective: To determine the correlation between serum calcium levels and the BISAP severity scale in the emergency department.
Materials and Methods: An observational, analytical study was done with records of patients with acute pancreatitis in the emergency department of a general hospital from January to December 2019. The correlation formula was used to calculate the sample size. The sampling technique was non-probabilistic by quota. Calcium and BISAP were measured at admission and at 48 hours, calcium on a continuous and BISAP on a discrete scale. Pearson correlation, regression and projections were made.
Results: There were included 90 patients. At admission, the correlation (-0.405) between BISAP (discrete scale) and serum calcium (continuous scale) was statistically significant (p = 0.000); the patient with BISAP 0 had calcium of 8.685 mg/dL and with BISAP 5 had serum calcium of 7.490 mg/dL. At 48 hours of admission, the correlation (-0.732) between BISAP and serum calcium was significant (p = 0.000), more intense and maintained the inversely proportional relationship.
Conclusions: The correlation between serum calcium and BISAPS is high and inversely proportional in acute pancreatitis.


REFERENCES

  1. Yadav D, Lowenfels AB. The epidemiology of pancreatitisand pancreatic cancer. Gastroenterology 2013; 144 (6):1252-1261. doi: 10.1053/j.gastro.2013.01.068.

  2. Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, et al AmericanGastroenterological Association Institute Guidelineon Initial Management of Acute Pancreatitis. Gastroenterology2018; 154: 1096-1101. https://doi.org/10.1053/j.gastro.2018.01.032.

  3. Garber A, Frakes C, Arora Z, Chahal P. Mechanisms andmanagement of acute pancreatitis. Gastroenterol Res Pract2018; 1-8. doi: 10.1155/2018/6218798.

  4. De Waele JJ. Acute pancreatitis. Curr Opin Crit Care 2014;20: 189-95. doi: 10.1097/MCC.0000000000000068.

  5. Fagenholz PJ, Fernández-del Castillo CF, Harris NS, PelletierAJ, et al. Increasing United States hospital admissions foracute pancreatitis, 1988-2003. Ann Epidemiol 2007; 17:491. doi: 10.1016/j.annepidem.2007.02.002.

  6. Díaz C, Garzón S, Morales CH. et al. Pancreatitis agudagrave: curso clínico, manejo y factores asociados conmortalidad. Rev Colomb Cir 2012; 27: 281-9.

  7. Neoptolemos JP, Raraty M., Finch M, Sutton R. Acute pancreatitis:the substantial human and financial costs. Gut,1998; 42: 886-891. doi: 10.1136/gut.42.6.886.

  8. Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, et al.Double blind, randomised, placebo-controlled study of aplatelet activating factorantagonist, lexipafant, in the treatmentand prevention of organ failure in predicted severe acutepancreatitis. Gut, 2001;48: 62-69. doi: 10.1136/gut.48.1.62.

  9. Leppäniemi A, Tolonen M, Tarasconi A, Segovia H, et al.2019 WSES guidelines for the management of severeacute pancreatitis. World J Emerg Surg 2019; 14 (27): 1-20.https://doi.org/10.1186/s13017-019-0247-0.

  10. Wu BU, Johannes RS, Sun X, Tabak Y, et al. The early predictionof mortality in acute pancreatitis: a large populationbasedstudy. Gut 2008; 57 (12): 1698-703. doi: 10.1136/gut.2008.152702.

  11. Byung K, Myung N, Choong R, Hwa S, et al. A comparison ofthe BISAP score and serum procalcitonin for predicting theseverity of acute pancreatitis. Korean J Intern Med 2013;28: 322-329. doi: 10.3904/kjim.2013.28.3.322.

  12. Lizarazo JI. Fisiopatología de la pancreatitis aguda. Rev ColGastroenterol 2008; 23 (2): 187-191.

  13. Sánchez M. Pancreatitis aguda. Rev Med Int Med Crit2004; 1 (01):1-16.

  14. Gutiérrez-Jiménez AA, Castro-Jiménez E, Lagunes-CórdobaR. Calcio sérico total y calcio corregido como predictoresde severidad en pancreatitis aguda. Rev GastroenterolMéx 2014; 79 (1):13-21. DOI: 10.1016/j.rgmx.2013.08.003.

  15. Peery AF, Dellon ES, Lund J, Crockett SD, et al. Burden ofgastrointestinal disease in the United States: 2012 update.Gastroenterology 2012; 143: 1179-1187. doi: 10.1053/j.gastro.2012.08.002.

  16. Al Mofleh IA. Severe acute pancreatitis: Pathogenetic aspectsand prognostic factors. World J Gastroenterol 2008;14 (5): 675-684. doi: 10.3748/wjg.14.675.

  17. Clemens DL, Wells MA, Schneider KJ, Singh S. Molecularmechanisms of alcohol associated pancreatitis. WorldJ Gastrointest Pathophysiol 2014; 5 (3): 147-157. doi:10.4291/wjgp.v5.i3.147.

  18. Georg P, Apte M, Banks A. Acute pancreatitis. Lancet 2015;386: 85-96. doi: 10.1016/S0140-6736(14)60649-8.

  19. Wang GJ, Gao CF, Wei D, Wang C, et al. Acute pancreatitis:Etiology and common pathogenesis. World J Gastroenterol

  20. 2009; 15: 1427-1430. doi: 10.3748/wjg.15.1427.20. Silva-Vaz P, Abrantes AM, Castelo-Branco M, Gouvela A,et al. Multifactorial scores and biomarkers of prognosis ofacute pancreatitis: Applications to research and practice.Int J Mol Sci 2020; 21: 338. doi: 10.3390/ijms21010338.

  21. Meher S, Subhadarshan M, Kumar P, Rath S,. et al. Roleof biomarkers in diagnosis and prognostic evaluationof acute pancreatitis. J Biomarkers 2015; 1-13. doi:10.1155/2015/519534.

  22. Frossard JL, Steer ML, Pastor CM. Acute pancreatitis.Lancet 2008; 371: 143-52. https://doi.org/10.1016/S0140-6736(08)60107-5.

  23. Pandol SJ, Saluja AK, Imrie CW, Banks PA. Acute pancreatitis:Bench to the bedside. Gastroenterology 2007; 132:1127-1151. doi: 10.1053/j.gastro.2007.01.055.

  24. Brisinda G, Vanella S, Crocco A, Mazzari A, et al.Severe acute pancreatitis: advances and insights inassessment of severity and management. Eur J GastroenterolHepatol 2011; 23: 541-551. doi: 10.1097/MEG.0b013e328346e21e.




2020     |     www.medigraphic.com